Niels Riedemann
Company: Inflarx
Job title: Chief Executive Officer
Seminars:
Panel Discussion: Understanding the Current Attitudes Towards Mandatory Vaccinations Before Dosing a Patient with Complement Inhibitors 4:00 pm
Re-evaluating the blanket vaccination requirements for complement inhibitors considering the emergence of novel, non-C5 complement inhibitors that show a lower infection risk compared to earlier C5 antibodies Discussing whether a blanket-approach remains justified, or whether a more nuance, risk stratified approach is warranted Navigating vaccination in acute vs chronic complement-mediated conditions, to mitigate infection risk…Read more
day: End of Day Two
The Oral C5aR Inhibitor INF904 for the Treatment of Chronic Inflammatory Diseases & Beyond 2:30 pm
INF904 – C5aR inhibitor with best-in-class potential C5aR inhibition in Hidradenitis Suppurativa C5aR inhibition in Chronic Spontaneous UrticariaRead more
day: Conference Day One